Browse News
Filter News
Found 44 articles
-
HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting
5/22/2023
HiberCell today announced dosing of the first patient in a Phase 1b clinical trial investigating the effects of odetiglucan, a first-in-class immunomodulatory agent, in combination with the CD40 agonistic monoclonal antibody, CDX-1140, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the maintenance setting.
-
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/24/2023
HiberCell today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
-
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)
2/22/2023
HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance and cancer relapse, today announced data from a recent poster presentation at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, which took place from January 23-25, 2023 in Austin, Texas.
-
Chimeron Bio Welcomes Kevin Heyeck as New CEO
12/13/2022
Chimeron Bio, an RNA company developing self-amplifying RNA vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced that Kevin Heyeck had been named Chief Executive Officer.
-
HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/2/2022
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced two clinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.
-
Combination Cancer Immunotherapy Expand Treatment Options in Breast Cancer
6/8/2022
In recent times, immunotherapy has emerged out to be most exciting paradigm change in cancer treatment. Since its initial approval in breast cancer, it has become the standard mode of treatment for wide subtypes of breast cancer.
-
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
5/24/2022
HiberCell announced that it will present the background and design of two clinical trials of the Company’s therapeutic candidates, odetiglucan and HC-7366, in individual poster presentations at the 2022 Annual Meeting of the American Society of Clinical Oncology, which will be held in person and virtually on June 3-7, 2022 in Chicago, Illinois.
-
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
-
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
4/28/2022
HiberCell today announced that the first patients have been dosed in a Phase 2 clinical trial of odetiglucan plus KEYTRUDA ® (pembrolizumab) for the treatment of metastatic, hormone-refractory breast cancer in adults.
-
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment
3/3/2022
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, announced today an in-person presentation on the clinical applications of the Company’s odetiglucan treatment for patients with metastatic and late-stage cancer at the Keystone Symposia, Myeloid Cells: From Birth to Immunity and Disease taking place March 6-9, 2022 in Banff, AB, Canada.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors
2/24/2022
HiberCell has initiated a Phase 1a/b clinical trial of HC-7366, a first-in-class selective, orally bioavailable modulator of General Control Nonderepressible 2 (GNC2) for the treatment of patients with advanced solid tumors.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer
12/14/2021
HiberCell announced a clinical trial collaboration with Merck, known as MSD outside of the United States and Canada.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021
12/9/2021
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, will deliver a virtual presentation on the clinical applications of our odetiglucan therapy for patients with metastatic and late-stage cancer at the ESMO Immuno-Oncology Virtual Congress 2021, December 8-11, 2021.
-
HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium
12/7/2021
HiberCell will present new data from the ongoing phase 2 open-label clinical trial evaluating the company’s odetiglucan (Imprime PGG) at the 2021 San Antonio Breast Cancer Symposium (SABCS) from December 7-10, 2021.
-
HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19
10/26/2021
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, and its academic collaborators in Strasbourg (France) published data from a study focused on defining biological networks believed responsible for severe and often deadly acute respiratory distress syndrome (ARDS) in a younger COVID-19 patient cohort.
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer
9/30/2021
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.